Bluejay Diagnostics, INC

Bluejay Diagnostics announced the successful completion of patient enrollment in its SYMON-II clinical validation study, enrolling 750 patients ahead of schedule.

Bluejay Diagnostics stockholders approved a stock plan amendment and authorized a potential reverse stock split.

Bluejay Diagnostics has completed a private placement of common stock and warrants, raising $8.5 million in gross proceeds to fund FDA approval efforts and operations.

Bluejay Diagnostics has entered into a strategic manufacturing agreement with Argonaut Manufacturing Services to establish scalable U.S.-based production for its Symphony platform.

Bluejay Diagnostics reports Q1 2026 progress on its Symphony IL-6 test, with strong enrollment in its pivotal SYMON-II study and advancements in manufacturing readiness.

Bluejay Diagnostics announced the successful enrollment of 624 patients in its SYMON-II pivotal clinical trial for the Symphony platform, nearing its target of 750 patients.

Bluejay Diagnostics reports a net loss of $1.92 million for Q1 2026 and highlights substantial doubt about its ability to continue as a going concern, requiring at least $20 million in new capital by the end of 2027.

Bluejay Diagnostics reports continued net losses and substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

Bluejay Diagnostics reports substantial doubt about its ability to continue as a going concern, needing immediate capital to avoid potential liquidation.

Bluejay Diagnostics' Q1 2025 results reveal a net loss of $1.86 million and highlight substantial doubt about the company's ability to continue as a going concern without securing significant additional funding.

Bluejay Diagnostics' Q3 2024 report reveals ongoing financial losses, manufacturing delays, and concerns about the company's ability to continue as a going concern.

Bluejay Diagnostics reported a net loss of $4.8 million for the six months ended June 30, 2024, and faces challenges related to its Nasdaq listing and going concern status.

Bluejay Diagnostics reported significant losses, a going concern warning, and critical funding needs to advance its Symphony platform and FDA submission.

Bluejay Diagnostics files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and recent board composition changes.

Bluejay Diagnostics faces substantial financial challenges and is pursuing FDA approval for its Symphony platform by Q3 2028, contingent on securing significant funding and overcoming technical hurdles.

Bluejay Diagnostics' 10-K filing outlines its capital structure, ongoing financial challenges, and risks associated with its business and technology.

Bank Of America Corp /De/ and 2 others reported changes in beneficial ownership of Bluejay Diagnostics, Inc. common stock on July 21, 2026.

Hrt Financial Lp reported changes in beneficial ownership of Bluejay Diagnostics, Inc. common stock on July 9, 2026.

Bank of America entities, including Bank of America Corp., Bank of America N.A., and BofA Securities, Inc., have jointly filed a Form 4 indicating their beneficial ownership of Bluejay Diagnostics, Inc. (BJDX) has fallen below the 10% threshold, no longer subjecting them to Section 16 reporting requirements.

Director Douglas Clark Wurth acquired 12,500 shares of Bluejay Diagnostics common stock in a private placement transaction.

CEO Indranil Dey acquired 12,500 shares of Bluejay Diagnostics common stock in a private placement transaction.

Director Donald R. Chase acquired 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement.

Bluejay Diagnostics, Inc. has provided a 2025 mid-year business and corporate update, highlighting progress in its SYMON-II clinical study for sepsis diagnostics, ongoing manufacturing efforts, and recent financial activities including a capital raise and cost-saving measures, while facing substantial losses and Nasdaq listing challenges.

Bluejay Diagnostics is holding its annual meeting on June 18, 2025, to vote on director elections, reverse stock splits, and the ratification of its accounting firm.

Bluejay Diagnostics has amended its bylaws to reduce the quorum requirement for its upcoming Special Meeting of Stockholders to one-third of the shares entitled to vote.

Bluejay Diagnostics is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of institutional investors.

Bluejay Diagnostics is holding a special meeting to seek stockholder approval for increasing authorized shares and ratifying the issuance of Class C and Class D warrants related to a recent offering.

Bluejay Diagnostics is asking stockholders to vote on proposals including increasing authorized shares and implementing a reverse stock split at its annual meeting on May 14, 2024.

Bluejay Diagnostics is offering 2,906,977 units, each consisting of one share of common stock (or a prefunded warrant), two Class C warrants, and one Class D warrant, to raise capital for FDA approval activities and debt repayment.

Bluejay Diagnostics is offering units consisting of common stock or pre-funded warrants, along with Class C and Class D warrants, in a firm commitment underwritten offering.

NorthStrive Fund II LP and Manager Braeden Lichti have liquidated their entire stake in Bluejay Diagnostics, Inc., marking a complete exit from the company.

Braeden Lichti and Northstrive Fund II LP have filed an exit notice confirming the sale of their entire stake in Bluejay Diagnostics, Inc.

Intracoastal Capital LLC and its principals have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Bluejay Diagnostics, Inc.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 51,061 shares, representing 4.99% of the outstanding common stock of Bluejay Diagnostics, Inc.

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership in Bluejay Diagnostics, Inc.

Northstrive Fund II LP and its manager, Braeden Lichti, have disclosed significant beneficial ownership in Bluejay Diagnostics, Inc., with Lichti now holding over 5% of common stock.

Braeden Lichti and Northstrive Fund II LP have disclosed a combined 5.01% beneficial ownership stake in Bluejay Diagnostics, Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% passive ownership stake in Bluejay Diagnostics, Inc. common stock.